{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:30:12Z","timestamp":1791304212892,"version":"4.3.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The Chikungunya virus (CHIKV) is a mosquito-borne virus with a long history of recurring epidemics transmitted through <jats:italic>Aedes<\/jats:italic> mosquitoes. The rapid spread of CHIKV has intensified the need for potent vaccines. Escherichia coli (<jats:italic>E.coli<\/jats:italic>), a vital part of human gut microbiota, is utilized in recombinant DNA technology for cloning. However, its high adaptability can lead to severe infections in humans. This study aimed to develop the candidate dual vaccine against CHIKV and <jats:italic>E. coli.<\/jats:italic> For this, we expressed the CHIKV E2 protein in the <jats:italic>E. coli<\/jats:italic> Rosetta Bl21 cells and the protein expression was confirmed by western blotting. The IgG immune response of the candidate vaccine was determined against CHIKV and <jats:italic>E. coli<\/jats:italic> by ELISA. Further, the potential of antibodies to neutralize CHIKV was evaluated via Tissue Culture Infectious Dose 50 (TCID50). We observed that cells expressing E2 protein with alum immunized mice serum showed a five-fold higher IgG immune response against CHIKV, compared to control cells. The CHIKV neutralization assay results showed a two-fold decrease in CHIKV TCID50 value after 12 hours and a three-fold reduction after 120 hours. Similarly, the vaccine formulation also elicited a significantly higher IgG immune response against <jats:italic>E. coli<\/jats:italic>. The results suggested that expressing CHIKV E2 protein in <jats:italic>E. coli<\/jats:italic> is a potential approach for generating an IgG immune response against CHIKV and <jats:italic>E. coli<\/jats:italic> both. This study proposes a faster, safer, and cost-effective recombinant protein-based vaccine development.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1500622","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:15:31Z","timestamp":1736234131000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of heat-killed E. coli expressing Chikungunya virus E2 protein as a candidate vaccine for dual protection against Chikungunya virus and E. coli"],"prefix":"10.3389","volume":"15","author":[{"given":"Surajit","family":"Patra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra","family":"Gajbhiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh A.","family":"Karpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1086\/605496","article-title":"Chikungunya fever: An epidemiological review of a re-emerging infectious disease","volume":"49","author":"Erin Staples","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000623","article-title":"Chikungunya: A potentially emerging epidemic","volume":"4","author":"Thiboutot","year":"2010","journal-title":"PloS Negl Trop Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82858-0","article-title":"Changing patterns of chikunya virus: Re-emergence of a zoonotic arbovirus","volume":"88","author":"Powers","year":"2007","journal-title":"J Gen Virol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.crimmu.2021.03.001","article-title":"Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses","volume":"2","author":"Amaral","year":"2021","journal-title":"Curr Res Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.744164","article-title":"Overview on chikungunya virus infection: from epidemiology to state-of-the-art experimental models","volume":"12","author":"Constant","year":"2021","journal-title":"Front Microbiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-23969-0","article-title":"Deciphering the dark proteome of Chikungunya virus","volume":"8","author":"Singh","year":"2018","journal-title":"Sci Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84417","article-title":"Chikungunya virus: Epidemiology, replication, disease mechanisms, and prospective intervention strategies","volume":"127","author":"Silva","year":"2017","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/rrtm.s370046","article-title":"Development and application of treatment for chikungunya fever","volume":"13","author":"Millsapps","year":"2022","journal-title":"Res Rep Trop Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0007316","article-title":"Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice","volume":"13","author":"Ar\u00e9valo","year":"2019","journal-title":"PloS Negl Trop Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1101197","article-title":"Chikungunya vaccines in development","volume":"12","author":"Schwameis","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"B11","unstructured":"FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus\n          \n          \n          \n          2023"},{"key":"B12","first-page":"6","article-title":"Valneva awarded FDA fast track designation for chikungunya vaccine candidate","volume":"51","author":"Bender","year":"2018"},{"key":"B13","volume-title":"Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate Investor Contact: Media Contact","author":"Kieffer","year":"2020"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro818","article-title":"Pathogenic escherichia coli","volume":"2","author":"Kaper","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.9.3497-3503.1996","article-title":"The Escherichia coli K-12 gntP gene allows E. coli F-18 to occupy a distinct nutritional niche in the streptomycin-treated mouse large intestine","volume":"64","author":"Sweeney","year":"1996","journal-title":"Infect Immun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1128\/cmr.11.1.142","article-title":"Diarrheagenic escherichia coli","volume":"11","author":"Nataro","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011082","volume-title":"Broad protective vaccination against systemic Escherichia coli with\nautotransporter antigens","author":"Xing","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fitd.2021.709907","article-title":"Confronting challenges to enterotoxigenic escherichia coli vaccine development","volume":"2","author":"Fleckenstein","year":"2021","journal-title":"Front Trop Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.22038\/IJBMS.2022.63775.14053","article-title":"Immunogenicity of inactivated Escherichia coli O157:H7 with Stx2B microparticle in mice","volume":"26","author":"Arshadi","year":"2022","journal-title":"Iran J Basic Med Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2020.02.025","article-title":"Heterogeneous nuclear ribonucleoproteins participate in hepatitis E virus replication","volume":"432","author":"Pingale","year":"2020","journal-title":"J Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2013.144","article-title":"Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses","volume":"23","author":"Wu","year":"2013","journal-title":"Cell Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2016.0024","article-title":"Differential immune responses in mice immunized with recombinant neutralizing epitope protein of hepatitis e virus formulated with liposome and alum adjuvants","volume":"29","author":"Joshi","year":"2016","journal-title":"Viral Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3390\/v11060578","article-title":"Establishment and comparison of pathogenicity and related neurotropism in two age groups of immune competent mice, C57BL\/6J using an Indian isolate of chikungunya virus (CHIKV)","volume":"11","author":"Jain","year":"2019","journal-title":"Viruses"},{"key":"B24","doi-asserted-by":"publisher","first-page":"111015","DOI":"10.1016\/j.mehy.2023.111015","article-title":"Potential health risks of mRNA-based vaccine therapy: A hypothesis","volume":"171","author":"Acevedo-Whitehouse","year":"2023","journal-title":"Med Hypotheses"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2022.04.007","article-title":"Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis","volume":"28","author":"Trougakos","year":"2022","journal-title":"Trends Mol Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-21039-z","article-title":"Identification of T helper (Th)1- and Th2-associated antigens of Cryptococcus neoformans in a murine model of pulmonary infection","volume":"8","author":"Firacative","year":"2018","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-199911000-00009","article-title":"Th1\/th2 cells","volume":"5","author":"Romagnani","year":"1999","journal-title":"Inflamm Bowel Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri856","article-title":"Roles of Fc receptors in autoimmunity","volume":"2","author":"Takai","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00410-0","article-title":"The role of IgG Fc receptors in antibody-dependent enhancement","volume":"20","author":"Bournazos","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nri2735.How","article-title":"How are T H 2-type immune responses initiated and amplified? $watermark-text $watermark-text $watermark-text","volume":"10","author":"Paul","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03413.x","article-title":"Type 2 innate immune responses and the natural helper cell","volume":"132","author":"Koyasu","year":"2011","journal-title":"Immunology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.02.023","article-title":"Biosecurity risks associated with vaccine platform technologies","volume":"40","author":"Sandbrink","year":"2022","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1500622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:15:38Z","timestamp":1736234138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1500622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2024.1500622"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1500622","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1500622"}}